# OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

> **NCT03750175** · — · COMPLETED · sponsor: **Karen-Lise Garm Spindler** · enrollment: 49 (actual)

## Conditions studied

- Colorectal Cancer Metastatic
- Circulating Tumor DNA
- KRAS Gene Mutation
- NRAS Gene Mutation
- BRAF Gene Mutation
- Epidermal Growth Factor Receptor Inhibitor

## Interventions

- **OTHER:** Plasma circulating DNA analysis

## Key facts

- **NCT ID:** NCT03750175
- **Lead sponsor:** Karen-Lise Garm Spindler
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03750175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03750175, "OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03750175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*